Follows initiation of Phase 1a/1b study in the U.S. Company plans to include clinical centers in China to broaden geographic representation and accelerate patient enrollment into the Phase 1a/1b study SAN DIEGO and SHANGHAI, May 6, 2024 /PRNewswire/ — Adcentrx Therapeutics (“Adcentrx”),…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.